Cutera Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Cutera şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

2.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi	2.1%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Cutera, Inc. (NASDAQ:CUTR) Looks Inexpensive After Falling 47% But Perhaps Not Attractive Enough

Aug 20

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 28% Dive

Jun 22

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Mar 14

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

Aug 11

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Apr 19

Cutera, Inc. (NASDAQ:CUTR) Shares Could Be 49% Below Their Intrinsic Value Estimate

Sep 01

Cutera: The 'AviClear' Sign To Get Bullish

Jun 22

Cutera (NASDAQ:CUTR) Is Carrying A Fair Bit Of Debt

May 27

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CUTR şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CUTR şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cutera Piyasaya Karşı Temettü Getirisi

CUTR temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CUTR)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (CUTR) (3 yıla kadar)	0%

Önemli Temettü: CUTR şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CUTR şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CUTR şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CUTR herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Cutera Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Cutera Receives Deficiency Notice from Nasdaq Regarding Minimum $15 Million Market Value of Publicly Held Shares Requirement under Nasdaq Marketplace Rule 5450(b)(3)(C)

Consensus EPS estimates fall by 16%

Third quarter 2024 earnings: EPS misses analyst expectations

New major risk - Market cap size

Cutera, Inc. Reaffirms Financial Guidance for the Full Year 2024

Cutera, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cutera Receives Deficiency Notice from Nasdaq Regarding Listing Rule 5450(a)(1)

Cutera, Inc. (NASDAQ:CUTR) Looks Inexpensive After Falling 47% But Perhaps Not Attractive Enough

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. Revises Revenue Guidance for the Year 2024

High number of new and inexperienced directors

Cutera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cutera, Inc.(NasdaqGS:CUTR) dropped from Russell 3000 Index

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 28% Dive

Price target decreased by 17% to US$6.33

High number of new and inexperienced directors

Cutera, Inc., Annual General Meeting, Jul 15, 2024

Cutera, Inc. Reiterates Earnings Guidance for 2024

Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024

Cutera, Inc. Announces North America Launch of xeo+

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Cutera, Inc. announced delayed annual 10-K filing

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Consensus EPS estimates fall by 33%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 59% to US$7.67

High number of new and inexperienced directors

Cutera, Inc. Revises Revenue Guidance for the Full Year 2023

Cutera, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-Q

Cutera, Inc. announced delayed 10-Q filing

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

New minor risk - Market cap size

Cutera, Inc. Appoints Brent Hauser as President, International

Cutera, Inc. Announces the Launch of New Skin Resurfacing and Revitalization Platform Secret DUO

President recently bought US$297k worth of stock

Cutera, Inc. Appoints Jeffrey Jones as Chief Operating Officer, Effective August 28, 2023

Consensus revenue estimates fall by 14%

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.9% to US$23.00

Cutera, Inc. Provides Revenue Guidance for the Full Year 2023

Cutera, Inc. Appoints Talyor C. Harris as President, Effective August 7, 2023

Cutera, Inc. Announces CEO Changes, Effective August 7, 2023

Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023

the Gross Law Firm Notifies Shareholders of Cutera, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 24, 2023

Cutera, Inc. Announces A New U.S. Food and Drug Administration Clearance of AviClear as A Long-Term Treatment for Mild to Severe Inflammatory Acne Vulgaris

Cutera, Inc. Announces Resignation of J. Daniel Plants as Director

Independent Director notifies of intention to sell stock

Cutera, Inc. Announces Resignation of Joseph E. Whitters from the Board of Directors

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Cutera, Inc

Less than half of directors are independent

Cutera, Inc. Announces Board Changes

Cutera, Inc. Appoints Stuart Drummond as Interim Chief Financial Officer

Voce Capital and David Mowry Terminate Proxy Solicitation

Cutera, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 57%

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Does Cutera (NASDAQ:CUTR) Have A Healthy Balance Sheet?

Price target decreased to US$61.20

Cutera, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Cutera, Inc. Announces AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.077 loss in 3Q 2021)

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Cutera, Inc. Announces Committee Appointments

Cutera, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Would Cutera (NASDAQ:CUTR) Be Better Off With Less Debt?

Cutera, Inc. Announces Resignation of Katherine S. Zanotti from the Board